Success Metrics

Clinical Success Rate
90.9%

Based on 328 completed trials

Completion Rate
91%(328/361)
Active Trials
155(23%)
Results Posted
3%(10 trials)
Terminated
33(5%)

Phase Distribution

Ph phase_4
14
2%
Ph phase_2
13
2%
Ph early_phase_1
3
0%
Ph phase_1
8
1%
Ph not_applicable
328
48%
Ph phase_3
9
1%

Phase Distribution

11

Early Stage

13

Mid Stage

23

Late Stage

Phase Distribution375 total trials
Early Phase 1First-in-human
3(0.8%)
Phase 1Safety & dosage
8(2.1%)
Phase 2Efficacy & side effects
13(3.5%)
Phase 3Large-scale testing
9(2.4%)
Phase 4Post-market surveillance
14(3.7%)
N/ANon-phased studies
328(87.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.4%

328 of 371 finished

Non-Completion Rate

11.6%

43 ended early

Currently Active

155

trials recruiting

Total Trials

680

all time

Status Distribution
Active(186)
Completed(328)
Terminated(43)
Other(123)

Detailed Status

Completed328
Recruiting129
unknown122
Terminated33
Not yet recruiting28
Active, not recruiting26

Development Timeline

Analytics

Development Status

Total Trials
680
Active
155
Success Rate
90.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (0.8%)
Phase 18 (2.1%)
Phase 213 (3.5%)
Phase 39 (2.4%)
Phase 414 (3.7%)
N/A328 (87.5%)

Trials by Status

withdrawn101%
completed32848%
unknown12218%
active_not_recruiting264%
not_yet_recruiting284%
enrolling_by_invitation30%
terminated335%
recruiting12919%
suspended10%

Recent Activity

Clinical Trials (680)

Showing 20 of 680 trialsScroll for more
NCT02453620Phase 1

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Active Not Recruiting
NCT06796114Not Applicable

Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

Recruiting
NCT06320717

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Recruiting
NCT02530658

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

Recruiting
NCT03810859Not Applicable

Non-syndromic Inherited Anomalies of Mineralized Tooth Tissues: a Whole Exome Study to Identify New Pathogenic Variants

Completed
NCT06782451Not Applicable

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

Recruiting
NCT03985696Not Applicable

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

Completed
NCT05233267

Neopterin on Admission to Intensive Care Unit

Active Not Recruiting
NCT06390436Phase 4

Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

Not Yet Recruiting
NCT07686653

A Study of the Value of Trio Genome Sequencing in the Etiological Evaluation of Early-Onset and/or Atypical Psychiatric Disorders Without Intellectual Disability or Congenital Anomalies

Not Yet Recruiting
NCT03849716

Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)

Completed
NCT03912129Not Applicable

Autoimmune Cytopenia: Genetics and Pathophysiological Mechanism in Pediatric Evans Syndrome

Completed
NCT03873727Phase 2

Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.

Completed
NCT06861244Phase 2

Embryonal Tumor With Multilayered Rosettes

Recruiting
NCT05458622Phase 3

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol

Active Not Recruiting
NCT05621850Not Applicable

Impact of CErebral Endovascular PROcedures on the Systemic Immune responSe Response

Active Not Recruiting
NCT05747651

3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2

Completed
NCT05671159Not Applicable

COMPArative Study of the Consequence on innaTe Immune Response du to Bacterial or Viral Infection in Patients Admitted to Intensive Care Unit

Active Not Recruiting
NCT03347760Not Applicable

Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis

Completed
NCT06147843Not Applicable

French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
680